In the phase II ATLANTIC study of single-agent durvalumab as third-line or later treatment for advanced NSCLC, OR rate and DC rate at 6 months in 102 patients with EGFRm, ALK-positive disease, regardless of PD-L1 expression, were 9.8% and 16.7%, respectively, and median DoR was 7.4–7.9 months [36], indicating limited antitumor activity with durvalumab monotherapy in this setting. The gene discussed is ALK; the disease is non-small cell lung carcinoma.